PCN71 Budget IMPACT Analysis of Zanubrutinib for the Treatment of Adult Patients with Mantle Cell Lymphoma WHO Have Received at Least One PRIOR Therapy from the Payer Perspective in the United States
Dec 1, 2020, 00:00
10.1016/j.jval.2020.08.208
https://www.valueinhealthjournal.com/article/S1098-3015(20)32464-5/fulltext
Title :
PCN71 Budget IMPACT Analysis of Zanubrutinib for the Treatment of Adult Patients with Mantle Cell Lymphoma WHO Have Received at Least One PRIOR Therapy from the Payer Perspective in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32464-5&doi=10.1016/j.jval.2020.08.208
First page :
Section Title :
Open access? :
No
Section Order :
10160